Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher L Bowlus

Showing results (111-120 of 189) with videos related to

Pageof 19
Sort By:
The American Journal of Gastroenterology|November 19, 2025
Nebokitug, an Anti-chemokine (C-C Motif) Ligand 24 Monoclonal Antibody, in Patients With Primary Sclerosing Cholangitis: A Phase 2 StudyChristopher L Bowlus, Douglas Thorburn, Stephen T Barclay, et al.
Hepatology (Baltimore, Md.)|September 9, 2022
AASLD practice guidance on primary sclerosing cholangitis and cholangiocarcinomaChristopher L Bowlus, Lionel Arrivé, Annika Bergquist, et al.
Hepatology (Baltimore, Md.)|January 25, 2023
Reply: Insurance should cover vancomycin for primary sclerosing cholangitisChristopher L Bowlus, Lionel Arrivé, Annika Bergquist, et al.
The American Journal of Gastroenterology|March 2, 2026
Impact of Alkaline Phosphatase Normalization on Complication-Free Survival in Primary Biliary CholangitisAnish Reddy, Adrielly Martins, Christopher L Bowlus, et al.
Hepatology (Baltimore, Md.)|February 2, 2023
Reply: Living donor liver transplantation for people with PSCLisa M Forman, Gonzalo Sapisochin, David N Assis, et al.
Alimentary Pharmacology & Therapeutics|April 3, 2026
Seladelpar Improved Itch, Itch-Related Sleep Disturbance and Measures of Fatigue in Patients With Primary Biliary Cholangitis and Pruritus in the Phase 3 RESPONSE TrialCynthia Levy, David E J Jones, Marlyn J Mayo, et al.
The Lancet. Gastroenterology & Hepatology|March 30, 2019
Long-term efficacy and safety of obeticholic acid for patients with primary biliary cholangitis: 3-year results of an international open-label extension studyMichael Trauner, Frederik Nevens, Mitchell L Shiffman, et al.
JHEP Reports : Innovation in Hepatology|December 3, 2024
Fecal deoxycholic acid associates with diet, intestinal microbes, and total bilirubin in primary sclerosing cholangitisConnie Chan, Mateus Lemos, Peter Finnegan, et al.
Hepatology Communications|May 14, 2025
Treatment of pruritus in primary sclerosing cholangitis: Analysis of the consortium for autoimmune liver disease registryRichard Dean, Maryam Yazdanfar, Joseph Zepeda, et al.
Hepatology (Baltimore, Md.)|June 23, 2010
Biliary apotopes and anti-mitochondrial antibodies activate innate immune responses in primary biliary cirrhosisAna Lleo, Christopher L Bowlus, Guo-Xiang Yang, et al.
Pageof 19

Showing results (111-120 of 189) with videos related to

Sort By:
Pageof 19
The American Journal of Gastroenterology|November 19, 2025
Nebokitug, an Anti-chemokine (C-C Motif) Ligand 24 Monoclonal Antibody, in Patients With Primary Sclerosing Cholangitis: A Phase 2 StudyChristopher L Bowlus, Douglas Thorburn, Stephen T Barclay, et al.
Hepatology (Baltimore, Md.)|September 9, 2022
AASLD practice guidance on primary sclerosing cholangitis and cholangiocarcinomaChristopher L Bowlus, Lionel Arrivé, Annika Bergquist, et al.
Hepatology (Baltimore, Md.)|January 25, 2023
Reply: Insurance should cover vancomycin for primary sclerosing cholangitisChristopher L Bowlus, Lionel Arrivé, Annika Bergquist, et al.
The American Journal of Gastroenterology|March 2, 2026
Impact of Alkaline Phosphatase Normalization on Complication-Free Survival in Primary Biliary CholangitisAnish Reddy, Adrielly Martins, Christopher L Bowlus, et al.
Hepatology (Baltimore, Md.)|February 2, 2023
Reply: Living donor liver transplantation for people with PSCLisa M Forman, Gonzalo Sapisochin, David N Assis, et al.
Alimentary Pharmacology & Therapeutics|April 3, 2026
Seladelpar Improved Itch, Itch-Related Sleep Disturbance and Measures of Fatigue in Patients With Primary Biliary Cholangitis and Pruritus in the Phase 3 RESPONSE TrialCynthia Levy, David E J Jones, Marlyn J Mayo, et al.
The Lancet. Gastroenterology & Hepatology|March 30, 2019
Long-term efficacy and safety of obeticholic acid for patients with primary biliary cholangitis: 3-year results of an international open-label extension studyMichael Trauner, Frederik Nevens, Mitchell L Shiffman, et al.
JHEP Reports : Innovation in Hepatology|December 3, 2024
Fecal deoxycholic acid associates with diet, intestinal microbes, and total bilirubin in primary sclerosing cholangitisConnie Chan, Mateus Lemos, Peter Finnegan, et al.
Hepatology Communications|May 14, 2025
Treatment of pruritus in primary sclerosing cholangitis: Analysis of the consortium for autoimmune liver disease registryRichard Dean, Maryam Yazdanfar, Joseph Zepeda, et al.
Hepatology (Baltimore, Md.)|June 23, 2010
Biliary apotopes and anti-mitochondrial antibodies activate innate immune responses in primary biliary cirrhosisAna Lleo, Christopher L Bowlus, Guo-Xiang Yang, et al.
Pageof 19